

Index

- acamprosate, alcohol dependence, 223–225, 227–228, 252
- acetylcholine, role in Alzheimer's disease, 263
- aerobic exercise, panic disorder, 81
- agitation, schizophrenia sedation strategies, 21
- agomelatine, 63, 119
- agranulocytosis, 20
- alcohol dependence, 214–215, 222–228, 251–254
- alprazolam
 generalized anxiety disorder (GAD), 113
 panic disorder, 75, 77–78
 personality disorders, 287, 304
 post-traumatic stress disorder (PTSD), 174, 177, 180
 social anxiety disorder (SAD), 91, 96
- Alzheimer's disease (AD)
 assessment and diagnosis, 266–267
 conclusions on pharmacotherapy, 272
 future therapeutic options, 271–272
 neuropathology and neurochemistry, 263
 overview of the disease, 262
 treatment strategies, 267–271
- amantadine, cocaine dependence, 245
- amineptine, eating disorders, 204
- amisulpride, schizophrenia, 19, 20, 22, 26
- amitriptyline
 eating disorders, 193, 195–196
 major depressive disorder (MDD), 54
- personality disorders, 283, 286–287
- post-traumatic stress disorder (PTSD), 174, 177
- amphetamine, attention deficit hyperactivity disorder (ADHD), 5–9, 11
- anorexia nervosa (AN)
 maintenance treatment, 206
 meta-analyses, 204
 pharmacotherapy of, 191–196
 treatment guidelines, 205–206
 treatment-resistant case management, 207
- anticonvulsant drugs. *See* antiepileptic/anticonvulsant drugs
- antidepressant drugs. *See also specific drugs/drug types*
- alcohol dependence, 227–228
- Alzheimer's disease (AD), 271
- bipolar disorder, 40, 42–43, 48
- cannabis dependence, 249–251
- cocaine dependence, 244
- major depressive disorder pharmacotherapy. *See* major depressive disorder (MDD)
- nicotine dependence, 216–219
- panic disorder, 77–82
- personality disorders, 279, 284, 305
- schizophrenia, 21–22
- social anxiety disorder (SAD), 94–96
- antiepileptic/anticonvulsant drugs. *See also specific drugs*
- alcohol dependence, 225
- cocaine dependence, 243–244
- eating disorders, 194, 199, 202–203, 205
- obsessive–compulsive disorder (OCD), 156
- panic disorder, 81
- personality disorders, 287–291, 293–295, 303–306
- post-traumatic stress disorder (PTSD), 174, 177, 185
- social anxiety disorder (SAD), 93, 96–97
- antihypertensive drugs, panic disorder, 81
- antiparkinson medication
 extrapyramidal side-effect management, 20
- schizophrenia, 22
- antipsychotic drugs. *See also specific drugs*
- acute schizophrenia treatment, 18–27
- Alzheimer's disease (AD), 270
- bipolar disorder, 44–48
- children and adolescents, 192–193
- cocaine dependence, 245
- eating disorders, 191–193, 205
- generalized anxiety disorder (GAD), 111, 119
- major depressive disorder (MDD), 60–61
- obsessive–compulsive disorder (OCD), 150–155
- panic disorder, 81, 82
- personality disorders, 279–281, 284–303, 306
- post-traumatic stress disorder (PTSD), 174, 177, 183–185
- schizophrenia maintenance treatment, 27–30
- schizophrenia treatment overview, 18

- social anxiety disorder (SAD), 93, 97
- antisocial personality disorder (AsPD), 281
- anxiolytic drugs. *See also specific drugs*
- nicotine dependence, 220
- appetite enhancers, eating disorders, 195
- aripiprazole
- bipolar disorder, 44, 48
- cocaine dependence, 245
- eating disorders, 192
- major depressive disorder (MDD), 61
- obsessive-compulsive disorder (OCD), 153–155
- personality disorders, 293, 302–303
- schizophrenia, 20–22, 25, 26
- asenapine, 19, 22, 44
- atenolol, social anxiety disorder (SAD), 93, 99
- atomoxetine
- attention deficit hyperactivity disorder (ADHD), 4, 5, 7–9, 11
- cannabis dependence, 250
- eating disorders, 201–202
- attention deficit hyperactivity disorder (ADHD)
- conclusions on management, 12
- first-line treatment, 4–9
- impact of pharmacotherapy, 9–10
- management of
- treatment-resistant cases, 12
- overview of the disorder, 1–3
- practice parameters, 3–4, 11
- treatment duration, 10–11
- avoidant personality disorder (AvPD), 296–301, 305–306
- baclofen
- alcohol dependence, 226, 228
- cannabis dependence, 250
- cocaine dependence, 248
- bapineuzumab, 271
- behavioral activation, treatment-related, 133
- behavioral and psychological symptoms of dementia (BPSD), 262, 270–271
- behavioral therapy. *See also* cognitive-behavioral therapy (CBT)
- attention deficit hyperactivity disorder (ADHD), 2–4
- benzodiazepines. *See also specific drugs*
- bipolar disorder, 44
- generalized anxiety disorder (GAD), 111–114, 116, 118
- obsessive-compulsive disorder (OCD), 150
- panic disorder, 75–78, 80, 82
- personality disorders, 304
- post-traumatic stress disorder (PTSD), 177, 180, 185
- schizophrenia, 21
- social anxiety disorder (SAD), 91, 96–100, 103–104
- beta-blockers. *See also specific drugs*
- obsessive-compulsive disorder (OCD), 150
- social anxiety disorder (SAD), 93, 96, 97, 103
- binge-eating disorder (BED)
- introduction, 190–191
- maintenance treatment, 206
- meta-analyses of
- pharmacotherapy, 205
- pharmacotherapy of, 200–203
- treatment guidelines, 205, 206
- treatment-resistant case management, 207
- bipolar disorder
- bipolar depression, 40–44, 58
- conclusions on
- pharmacotherapy, 49
- mania and mixed episodes, 44–45
- relapse prevention, 45–49
- bisphosphonates, eating disorders, 195
- borderline personality disorder (BPD), 278–279, 281–295, 305–307
- breast-feeding, generalized anxiety disorder (GAD)
- pharmacotherapy in, 120
- brofaromine
- eating disorders, 196–197
- personality disorders, 296–297, 305
- post-traumatic stress disorder (PTSD), 173, 175, 181–182
- social anxiety disorder (SAD), 98–100
- bromazepam, social anxiety disorder (SAD), 91, 96, 100
- bromocriptine, cocaine dependence, 245
- bulimia nervosa (BN)
- maintenance treatment, 206
- meta-analyses, 204–205
- pharmacotherapy of, 196–200
- treatment guidelines, 205–206
- treatment-resistant case management, 207
- buprenorphine
- cocaine dependence, 247
- opioid dependency, 240–242
- bupropion
- bipolar disorder, 43
- cannabis dependence, 250–251
- cocaine dependence, 245–246
- eating disorders, 199–200
- major depressive disorder (MDD), 55–56, 59, 60
- nicotine dependence, 216–219, 221
- panic disorder, 81
- buspirone
- cannabis dependence, 250
- generalized anxiety disorder (GAD), 112, 114, 116, 118
- major depressive disorder (MDD), 60
- nicotine dependence, 220
- obsessive-compulsive disorder (OCD), 149
- social anxiety disorder (SAD), 93, 96, 97–99, 102
- cabergoline, cocaine dependence, 245

Cambridge University Press

978-1-107-00795-6 - Essential Evidence-Based Psychopharmacology: Second edition

Edited by Dan J. Stein, Bernard Lerer and Stephen M. Stahl

Index

[More information](#)

318

Index

- cannabidiol (CBD), 250–251
- cannabis dependence, 235–236, 249–254
- carbamazepine
Alzheimer's disease (AD), 270
- bipolar disorder, 45, 48
- cocaine dependence, 243
- eating disorders, 199
- personality disorders, 287–288, 303
- cardiovascular risk, stimulant medication adverse effect, 6–7
- cariprazine, bipolar disorder, 44
- chlordiazepoxide, personality disorders, 282
- chlorpromazine
bipolar disorder, 45
- eating disorders, 191–192
- personality disorders, 285
- schizophrenia, 21, 24–25
- cholinesterase inhibitors. *See also specific drugs*
Alzheimer's disease (AD), 262–270, 272
- citalopram
cocaine dependence, 244
- eating disorders, 193, 200–202
- generalized anxiety disorder (GAD), 115
- major depressive disorder (MDD), 56, 58–60
- obsessive–compulsive disorder (OCD) first-line treatment, 133, 136, 139, 146
- panic disorder, 74–75, 78
- post-traumatic stress disorder (PTSD), 173, 176, 181–182
- social anxiety disorder (SAD), 95, 100, 102
- treatment-resistant OCD management, 147, 149, 153
- clomipramine
eating disorders, 193
- obsessive–compulsive disorder (OCD) dose studies, 139–140
- obsessive–compulsive disorder (OCD) first-line treatment, 129–131, 133, 135–138, 143
- obsessive–compulsive disorder (OCD) long-term use, 144, 145
- panic disorder, 74–75, 79–80
- treatment-resistant OCD management, 145–150, 153–154
- clonazepam
obsessive–compulsive disorder (OCD), 149
- panic disorder, 75, 77–78
- social anxiety disorder (SAD), 91, 96, 98–100, 103
- clonidine
attention deficit hyperactivity disorder (ADHD), 5, 9
- cannabis dependence, 250
- nicotine dependence, 220–221
- personality disorders, 292, 295, 304
- clorgyline, obsessive–compulsive disorder (OCD), 130
- clozapine
bipolar disorder, 48
- obsessive–compulsive disorder (OCD), 150, 154
- schizophrenia, 19–23, 25–26
- cocaine dependence, 235–236, 243–249, 251–254
- cocaine vaccine, 248
- cognitive–behavioral therapy (CBT)
eating disorders, 191–192, 200–203, 207
- generalized anxiety disorder (GAD), 119
- obsessive–compulsive disorder (OCD), 132, 138, 139, 154, 156–157
- panic disorder, 80–82
- social anxiety disorder (SAD), 98, 99, 101, 103
- compliance, schizophrenia treatment, 23
- cypheptadine, eating disorders, 195
- cytisine, nicotine dependence, 218
- cytochrome P450 enzyme system, 23
- D-cycloserine
obsessive–compulsive disorder (OCD), 156
- panic disorder, 82
- social anxiety disorder (SAD), 103
- delta-9-tetrahydrocannabinol (THC), 250–251
- dementia
Alzheimer's disease. *See* Alzheimer's disease (AD)
- definition of, 262
- Lewy Body, 264
- vascular, 266
- depot medication, schizophrenia, 20, 27–28
- depression
depressive symptoms in schizophrenia, 21–22
- major depressive disorder. *See* major depressive disorder (MDD)
- desipramine
cocaine dependence, 244
- eating disorders, 196
- obsessive–compulsive disorder (OCD), 130, 150
- personality disorders, 288
- post-traumatic stress disorder (PTSD), 174, 176
- desmethylclomipramine, obsessive–compulsive disorder (OCD), 149
- dexamphetamine, cocaine dependence, 245–246
- D-fenfluramine, eating disorders, 202
- dialectical behavioral therapy (DBT), 284, 292–293, 302
- diazepam
eating disorders, 195
- generalized anxiety disorder (GAD), 111, 116
- nicotine dependence, 220
- panic disorder, 75, 77–78
- disulfiram
alcohol dependence, 222–223, 225, 227
- cocaine dependence, 246–248
- divalproex
cannabis dependence, 250
- personality disorders, 290–291, 303

	Index	319
post-traumatic stress disorder (PTSD), 174, 177, 182 donepezil. <i>See also</i> cholinesterase inhibitors Alzheimer's disease (AD), 262–269 dopamine agonists, cocaine dependence, 245 dronabinol, 250 duloxetine generalized anxiety disorder (GAD), 111–112, 116–117, 119 panic disorder, 81 social anxiety disorder (SAD), 100 eating disorders (EDs) anorexia nervosa (AN) pharmacotherapy, 191–196, 204 binge-eating disorder (BED) pharmacotherapy, 200–203, 205 bulimia nervosa (BN) pharmacotherapy, 196–200, 204–205 children and adolescents, 192–193, 196, 197 conclusions and future research directions, 207–208 EDNOS (eating disorder not otherwise specified), 206 maintenance treatment, 206 meta-analyses, 204–205 night eating syndrome (NES) pharmacotherapy, 201, 203 treatment guidelines, 205–206 treatment-resistant case management, 207 electroconvulsive therapy (ECT), schizophrenia treatment, 27 escitalopram eating disorders, 200–202 generalized anxiety disorder (GAD), 111, 112, 114, 115–117 major depressive disorder (MDD), 54, 58	obsessive-compulsive disorder (OCD) first-line treatment, 133–136, 140, 141–142, 143–144 obsessive-compulsive disorder (OCD) treatment response prediction, 146 panic disorder, 75–76, 78 personality disorders, 300–301 social anxiety disorder (SAD), 92, 95 treatment-resistant OCD management, 149 etanercept, 271 ethyl-eicosapentaenoic acid (E-EPA), 291, 304 exercise, panic disorder, 81 exposure and response prevention (ERP) therapy, 156–157 extrapyramidal side-effects (EPS), 20–22 eye movement desensitization and reprocessing (EMDR), 176 family history, substance use disorders (SUDs), 253 fluoxetine anorexia nervosa (AN), 193, 205 binge-eating disorder (BED), 200–202 bipolar disorder, 41–42 bulimia nervosa (BN), 197–198, 205–206 children and adolescents, 193, 197 generalized anxiety disorder (GAD), 115–116 major depressive disorder (MDD), 57–58, 64 nicotine dependence, 219 obsessive-compulsive disorder (OCD) first-line treatment, 132–133, 136–137, 139, 144, 145–146 panic disorder, 74–75 personality disorders, 284, 288, 292, 302, 306 post-traumatic stress disorder (PTSD), 173, 175–176, 180–185	social anxiety disorder (SAD), 92, 95, 99–100 treatment-resistant OCD management, 147, 149–150, 152–153, 155 flupenthixol, personality disorders, 285, 302 fluphenazine personality disorders, 289 schizophrenia, 24–25 fluvoxamine eating disorders, 197–198, 200–202 obsessive-compulsive disorder (OCD) first-line treatment, 131–132, 136–137, 139, 145 panic disorder, 74–75 personality disorders, 284, 290, 296, 298–299 social anxiety disorder (SAD), 91, 95, 97, 98–99, 100 treatment-resistant OCD management, 146, 150, 153, 156 gabapentin alcohol dependence, 227–228 cocaine dependence, 243 personality disorders, 305 social anxiety disorder (SAD), 93, 96, 98–101, 103 galantamine. <i>See also</i> cholinesterase inhibitors Alzheimer's disease (AD), 262–269 major depressive disorder (MDD), 65 gambling, pathological, 251–254 gamma hydroxybutyric acid (GHB), alcohol dependence, 226–228 gamma-secretase inhibitors, 271 generalized anxiety disorder (GAD) conclusions on pharmacotherapy, 120 late-life, 119–120 major depressive disorder (MDD) comorbidity, 110, 116

Cambridge University Press

978-1-107-00795-6 - Essential Evidence-Based Psychopharmacology: Second edition

Edited by Dan J. Stein, Bernard Lerer and Stephen M. Stahl

Index

[More information](#)

320

Index

- generalized anxiety disorder (GAD) (*cont.*)
 optimal duration of continuation treatment, 116–118
 overview of disorder, 110–111
 pregnancy and breast-feeding, 120
 response rates in acute treatment studies, 111–115
 search strategy, 111
 treatment discontinuation symptoms, 118
 treatment response prediction, 115–116
 treatment tolerability concerns, 114–115
 treatment-resistant case management, 118–119
 glutamatergic agents. *See also specific drugs*
 emerging evidence in major depressive disorder (MDD), 63–64
 glycine, obsessive-compulsive disorder (OCD), 156
 guanfacine
 attention deficit hyperactivity disorder (ADHD), 5, 9
 personality disorders, 281
- haloperidol
 cocaine dependence, 245
 obsessive-compulsive disorder (OCD), 150, 152–155
 personality disorders, 285–288, 295, 302
 schizophrenia, 20–22, 24–26
 health related quality of life (HR-QoL), 141–142
 hepatotoxicity, atomoxetine adverse effect, 7
 heroin dependence, 235–242
 heroin-assisted treatment (HAT), 241–242, 247
 HIV, risk reduction in opioid dependency, 239
 hormone therapy, anorexia nervosa (AN), 195
 hydroxyzine, generalized anxiety disorder (GAD), 114–115
- iloperidone, 19, 22
 imipramine
 bipolar disorder, 42, 48
 eating disorders, 196, 206
 generalized anxiety disorder (GAD), 111, 118
 obsessive-compulsive disorder (OCD), 130
 panic disorder, 74–75, 77, 79–80
 personality disorders, 287
 post-traumatic stress disorder (PTSD), 174, 177
 impulsive aggression, 283–284, 305–306
 impulsive explosive disorder (IED), 284, 305
 inositol
 bipolar disorder, 43
 post-traumatic stress disorder (PTSD), 174, 179
 isocarboxazid, eating disorders, 196–197
- ketamine, major depressive disorder (MDD), 64
- lamotrigine
 bipolar disorder, 40, 42–43, 47–48
 cocaine dependence, 243
 eating disorders, 202–203
 major depressive disorder (MDD), 62
 obsessive-compulsive disorder (OCD), 156
 personality disorders, 293, 295, 303
 post-traumatic stress disorder (PTSD), 174, 177
 schizophrenia, 26
- latrepirdine, 271
 levetiracetam
 personality disorders, 305
 social anxiety disorder (SAD), 93, 97
 levodopa/carbidopa, cocaine dependence, 245
 Lewy Body dementia, 264
 lisdexamfetamine, 5, 246
 lithium
 anti-suicidal properties, 61–62
 bipolar disorder, 40, 43–46, 48
- cannabis dependence, 250
 eating disorders, 194, 199
 major depressive disorder (MDD), 61–62
 personality disorders, 281, 285, 288, 303
 treatment-resistant OCD management, 149
 lobeline, nicotine dependence, 218
 lofexidine, cannabis dependence, 250
 lorazepam
 generalized anxiety disorder (GAD), 113, 116
 panic disorder, 75, 77–78
 schizophrenia, 21
 loxapine, personality disorders, 285
- L-tryptophan, obsessive-compulsive disorder (OCD), 142, 150
- major depressive disorder (MDD)
 abstract, 53
 comorbid social anxiety disorder (SAD), 102
 conclusions on pharmacotherapy, 66
 continuation and maintenance, 58–59
 emerging evidence, 63–66
 first-line treatment, 53–55
 generalized anxiety disorder (GAD) comorbidity, 110, 116
 subpopulations and response predictors, 55–58
 suicide in children on SRI, 138–139
 treatment-resistant depression, 59–63
 mecamylamine, 218, 221
 memantine
 Alzheimer's disease (AD), 262–269, 271, 272
 major depressive disorder (MDD) treatment, 64
 obsessive-compulsive disorder (OCD), 155
 meprobamate, nicotine dependence, 220
 methadone
 cocaine dependence, 247

	Index	321
methadone maintenance treatment (MMT), 239–242	post-traumatic stress disorder (PTSD), 172–173	nicotine dependence, 214–222, 251–254
methamphetamine, cocaine dependence, 246	social anxiety disorder (SAD), 91, 94, 97–100, 104	nicotine vaccines, 220–221
methylene blue, 272	morphine, slow release oral (SROM), 242	night eating syndrome (NES), 201, 203
methylphenidate, attention deficit hyperactivity disorder (ADHD), 4–7, 8, 10–11	nalmefene, alcohol dependence, 223–224, 228	non-steroidal anti-inflammatory drugs (NSAIDs), Alzheimer's disease (AD), 271
metoprolol, nicotine dependence, 220	naloxone	nortriptyline
mianserin	nicotine dependence, 219	eating disorders, 204
obsessive–compulsive disorder (OCD), 142	opioid dependence, 241	major depressive disorder (MDD), 57, 60, 61
personality disorders, 285	personality disorders, 292, 305	nicotine dependence, 219, 221
midazolam, schizophrenia, 21	naltrexone	obsessive–compulsive disorder (OCD)
mild cognitive impairment (MCI), 267–268	alcohol dependence, 223–224, 226–228, 253	CBT vs. pharmacotherapy, 139
milnacipran, panic disorder, 81	cannabis dependence, 250	children, 131–133, 138–139, 142
Mini-Mental State Examination (MMSE), 266–267	cocaine dependence, 247–248	clomipramine as first-line treatment, 129–131, 135–138
mirtazapine	eating disorders, 195, 199	conclusions on pharmacotherapy, 157
eating disorders, 193	nicotine dependence, 219, 221	dose/dose titration, 139–141, 145
major depressive disorder (MDD), 54–55, 60	opioid dependence, 237–239, 242	health related quality of life (HR-QoL) improvement, 141–142
obsessive–compulsive disorder (OCD), 142, 149	personality disorders, 305	meta-analyses of SRIs' relative effectiveness, 137–138
panic disorder, 81	nefazodone	overview of disorder, 128–129
post-traumatic stress disorder (PTSD), 174, 179	cannabis dependence, 250–251	pharmacological alternatives to SRIs, 142–143
social anxiety disorder (SAD), 93, 95	post-traumatic stress disorder (PTSD), 174, 179, 182	review methods, 129
moclobemide	social anxiety disorder (SAD), 93, 95	selective serotonin reuptake inhibitors (SSRIs) as first-line treatment, 130–135, 136–139
panic disorder, 81	negative symptoms, schizophrenia, 22	study population changes and affect on treatment trial design, 135
personality disorders, 296–297, 305	neurofibrillary tangles (NFTs), 263, 272	suicide in children on SRI, 138–139
social anxiety disorder (SAD), 91, 94, 97–99	Neuropsychiatric Inventory (NPI), 271	treatment duration, 143–145
modafinil	nicotine	treatment response and relapse criteria, 142
cocaine dependence, 245–246	nicotine replacement therapy (NRT), 216–218, 221–222	treatment response predictors, 145–146
major depressive disorder (MDD), 64–65	obsessive–compulsive disorder (OCD), 156	treatment-resistant case management, 146–157
monoamine oxidase inhibitors (MAOIs). <i>See also specific drugs</i>	nicotine acetylcholinergic receptor (nAChR) agonists	
eating disorders, 196–197, 204	full/nicotine replacement therapy (NRT), 216–218, 221–222	
obsessive–compulsive disorder (OCD), 130	partial, 217–218	
panic disorder, 74–76, 78, 81	nicotine acetylcholinergic receptor (nAChR) antagonists, 218	
personality disorders, 284, 296–297, 305		

322	Index	
olanzapine	Alzheimer's disease (AD), 270	antisocial personality disorder (AsPD), 302
bipolar disorder, 41, 44, 46	borderline personality disorder (BPD), 290–295	cocaine dependence, 245
eating disorders, 191–193, 205	generalized anxiety disorder (GAD), 119	major depressive disorder (MDD), 61
obsessive–compulsive disorder (OCD), 152–155	panic disorder, 81	post-traumatic stress disorder (PTSD), 174, 177, 183–184
schizophrenia, 19–22, 24–25, 27	social anxiety disorder (SAD), 93, 97	ondansetron
alcohol dependence, 227–228	cocaine dependence, 244	eating disorders, 200
obsessive–compulsive disorder (OCD), 155	opioid agonists. <i>See also specific drugs</i>	cocaine dependence, 247
personality disorders, 304	opioid antagonists. <i>See also specific drugs</i>	alcohol dependence, 223–224
cannabis dependence, 250	cocaine dependence, 247–248	eating disorders, 195, 199
nicotine dependence, 219	personality disorders, 304	opioid dependence, 235–242, 251–254
orlistat, eating disorders, 203–204	oxazepam, personality disorders, 282	oxcarbazepine
bipolar disorder, 45, 48	personality disorders, 305	oxprenolol, nicotine dependence, 220
oxytocin, personality disorders, 306	paliperidone, 19, 22, 44	panic disorder
antidepressant drugs, 74–76	benzodiazepines, 77	conclusions on
pharmacotherapy, 82	importance of adequate care, 73–74	optimal duration of
pharmacotherapy, 78–80	optimal first-line	pharmacotherapy, 77–78
treatment-refractory patient approaches, 80–82	Parkinson's disease, associated dementia, 264	paroxetine
bipolar disorder, 40, 43	generalized anxiety disorder (GAD), 111–112, 114–115, 117–119	nicotine dependence, 219
obsessive–compulsive disorder (OCD), 133–135, 136–137, 139, 141–142, 143–144	panic disorder, 74–76, 78	personality disorders, 284, 289, 298–300
post-traumatic stress disorder (PTSD), 173, 175, 180–182, 184–185	social anxiety disorder (SAD), 91, 95, 98–103	treatment-resistant OCD management, 147, 150
pathological gambling, 251–254	pediatrics	antipsychotic drugs, 192–193
eating disorders, 192–193, 196, 197	obsessive–compulsive disorder (OCD), 131–133, 138, 142	selective serotonin reuptake inhibitors (SSRIs), 131–133, 138–139, 193, 197
social anxiety disorder (SAD), 104	suicidality risk, 138–139, 193	performance anxiety, 103–104
pergolide	cocaine dependence, 245	personality disorders, 281
perphenazine, schizophrenia, 20, 24, 25	personality disorders	antisocial personality disorder (AsPD), 281
avoidant personality disorder (AvPD), 296–301, 305	borderline personality disorder (BPD), 281–295, 305	future directions, 306–307
maladaptive traits, 305–306	schizotypal personality disorder (SPD), 279–281	pharmacogenetics
major depressive disorder (MDD), 65–66	substance use disorders (SUDs), 253	phenelzine
eating disorders, 196–197	panic disorder, 74–76, 78	personality disorders, 284, 287–288, 296–297, 305
post-traumatic stress disorder (PTSD), 172–173, 177	social anxiety disorder (SAD), 91, 94, 97, 98–101, 103	phenytoin
cocaine dependence, 243	eating disorders, 199, 202	personality disorders, 281
pimozide	eating disorders, 191	obsessive–compulsive disorder (OCD), 150
schizophrenia, 20	pindolol	obsessive–compulsive disorder (OCD), 150
social anxiety disorder (SAD), 103	piracetam, cocaine dependence, 248	post-traumatic stress disorder (PTSD)

conclusions on pharmacotherapy, 184–185 duration of treatment, 181–183 first-line treatment studies, 172–179 meta-analyses of pharmacotherapy, 179–181 treatment refractory cases, 183–184 pramipexole, major depressive disorder (MDD) treatment, 64 prazosin, posttraumatic stress disorder (PTSD), 183–185 pregabalin generalized anxiety disorder (GAD), 111, 114–119 personality disorders, 305 social anxiety disorder (SAD), 97, 101, 103 pregnancy, generalized anxiety disorder (GAD) pharmacotherapy in, 120 prokinetic agents, eating disorders, 195 prolactin increase, 20 promethazine, schizophrenia, 21 pro-motility agents, eating disorders, 205 propranolol, social anxiety disorder (SAD), 103 pseudoresistance, 59 psychotherapy attention deficit hyperactivity disorder (ADHD), 3–4 eating disorders, 191–192, 200–203, 207 generalized anxiety disorder (GAD), 119 obsessive–compulsive disorder (OCD), 132, 138, 139, 154, 156–157 panic disorder, 80–82 personality disorders, 278–279, 283, 306–307 post-traumatic stress disorder (PTSD), 180 social anxiety disorder (SAD), 98–99, 101, 103 substance use disorders (SUDs), 252	QT-prolongation, treatment-related, 20, 239–241, 270 quetiapine Alzheimer’s disease (AD), 270 bipolar disorder, 40–47, 49 cocaine dependence, 245 eating disorders, 191, 193, 205 generalized anxiety disorder (GAD), 113–119 major depressive disorder (MDD), 61 obsessive–compulsive disorder (OCD), 147, 152–155 schizophrenia, 20, 22, 24–25 social anxiety disorder (SAD), 97 reboxetine, panic disorder, 81 repetitive transcranial magnetic stimulation (rTMS) panic disorder, 81 schizophrenia, 27 reversible inhibitors of monoamine oxidase-A (RIMAs). <i>See also specific drugs</i> eating disorders, 197 personality disorders, 296–297, 305 post-traumatic stress disorder (PTSD), 172–175 social anxiety disorder (SAD), 91, 94 riluzole, 64, 115, 155 rimonabant cannabis dependence, 250 nicotine dependence, 220–221 risperidone Alzheimer’s disease (AD), 270 bipolar disorder, 43–44 cocaine dependence, 245 eating disorders, 192, 205 generalized anxiety disorder (GAD), 119 major depressive disorder (MDD), 61 obsessive–compulsive disorder (OCD), 150–155 personality disorders, 280	post-traumatic stress disorder (PTSD), 174, 177, 182–185 schizophrenia first-line treatment, 19–20, 22 schizophrenia maintenance treatment, 27, 29 social anxiety disorder (SAD), 97 treatment-resistant schizophrenia management, 22, 24–26 rivastigmine. <i>See also</i> cholinesterase inhibitors Alzheimer’s disease (AD), 262–269 S-adenosylmethionine (SAMe), 62–63 schizophrenia acute episode treatment, 18–27 maintenance treatment, 27–30 obsessive symptoms, 154 schizotypal personality disorder (SPD), 279–281, 306 scyllo-inositol, 271 sedation. <i>See also specific sedative drugs</i> agitation in schizophrenia, 21 bipolar disorder, 44 selective serotonin reuptake inhibitors (SSRIs). <i>See also specific drugs</i> alcohol dependence, 227 Alzheimer’s disease (AD), 271 children and adolescents, 131–133, 138–139, 193, 197 cocaine dependence, 244 eating disorders, 193, 197–198, 200–202, 204–206 generalized anxiety disorder (GAD), 111, 114–120 major depressive disorder (MDD), 53–60, 62–63 nicotine dependence, 219 obsessive–compulsive disorder (OCD), 130–157 panic disorder, 74–78, 80–81
--	--	---

Cambridge University Press

978-1-107-00795-6 - Essential Evidence-Based Psychopharmacology: Second edition

Edited by Dan J. Stein, Bernard Lerer and Stephen M. Stahl

Index

[More information](#)

324

Index

- selective serotonin reuptake inhibitors (SSRIs) (*cont.*)
 personality disorders, 284, 288–289, 292, 296–301, 305
 post-traumatic stress disorder (PTSD), 171–173, 175–176, 179–185
 pregnancy and breast-feeding, 120
 social anxiety disorder (SAD), 91, 94–95, 97–104
 selegiline, nicotine dependence, 219
 serotonin-norepinephrine reuptake inhibitors (SNRIs). *See also specific drugs*
 eating disorders, 202
 generalized anxiety disorder (GAD), 111, 114–115, 118–120
 obsessive–compulsive disorder (OCD), 143
 panic disorder, 74–76, 81
 post-traumatic stress disorder (PTSD), 176, 179
 pregnancy and breast-feeding, 120
 social anxiety disorder (SAD), 95, 100, 104
 sertindole, schizophrenia, 20, 22, 27
 sertraline
 eating disorders, 193, 197, 200–202, 205
 generalized anxiety disorder (GAD), 111, 112, 115
 major depressive disorder (MDD), 54, 56, 59
 nicotine dependence, 219
 obsessive–compulsive disorder (OCD) first-line treatment, 132, 136–137, 139–140, 144
 panic disorder, 74–75
 personality disorders, 296, 298, 305
 post-traumatic stress disorder (PTSD), 173, 176, 181–182, 185
 social anxiety disorder (SAD), 92, 95, 97, 100–101
 treatment-resistant OCD management, 147, 149
 sexual dysfunction, treatment-related, 115, 137, 141
 sibutramine, eating disorders, 202, 204–205
 sleep disturbance, treatment-related, 115
 slow release oral morphine (SROM), 242
 social anxiety disorder (SAD)
 children, 104
 comorbid psychiatric disorders, 102
 conclusions on pharmacotherapy, 104
 duration of pharmacotherapy, 101–102
 first-line treatment, 94–101
 non-generalized SAD treatment, 103–104
 treatment-resistant case management, 102–103
 social phobia, 296–301, 305–306
 St. John's Wort (SJW), nicotine dependence, 219
 stimulant medications. *See also specific drugs*
 attention deficit hyperactivity disorder (ADHD), 4–9, 11
 cocaine dependence, 245–246
 substance use disorders (SUDs)
 addiction neurobiology summary, 214–215
 alcohol dependence, 214–215, 222–228
 cannabis dependence, 249–251
 cocaine dependence, 243–249
 first and second line pharmacotherapy summary, 252
 introduction to illicit drug abuse, 235–236
 nicotine dependence, 214–222
 opioid dependence, 236–242
 overall conclusion, 251–254
 suicidality risk
 atomoxetine adverse effect, 7
 bipolar disorder, 45
 children/adolescents on SRIs, 138–139, 193
 lithium's anti-suicidal properties, 61–62
 major depressive disorder (MDD) patients, 56–57, 61–62
 nicotine dependence, 219
 panic disorder, 74
 personality disorders, 281–283, 302, 304
 selective serotonin reuptake inhibitors (SSRIs), 138–139, 193
 social anxiety disorder (SAD), 104
 sulpiride
 eating disorders, 191
 schizophrenia, 20, 26
 tamoxifen, bipolar disorder, 45
 taranabant, nicotine dependence, 220
 tetrahydrocannabinol (THC), eating disorders, 195
 thiothixene, personality disorders, 285
 tiagabine
 cocaine dependence, 244
 panic disorder, 81
 post-traumatic stress disorder (PTSD), 174, 177, 182–183
 topiramate
 alcohol dependence, 223, 225, 228
 cocaine dependence, 243–244
 eating disorders, 199, 202–203, 205, 207
 obsessive–compulsive disorder (OCD), 156
 personality disorders, 291, 293–294, 303–304
 post-traumatic stress disorder (PTSD), 174, 177, 182
 tranylcypromine
 bipolar disorder, 42
 major depressive disorder (MDD), 60

personality disorders, 284, 287	valproate	social anxiety disorder (SAD), 93, 95, 100
trazodone	bipolar disorder, 43–46, 48	vigabatrin
eating disorders, 200	cocaine dependence, 243	cocaine dependence, 243–244
generalized anxiety disorder (GAD), 111	schizophrenia treatment, 26	panic disorder, 81
panic disorder, 81	varenicline, nicotine dependence, 217–218, 221	weight gain, treatment-related, 115, 137
tricyclic antidepressants (TCAs). <i>See also specific drugs</i>	vascular dementia, 266	zinc supplementation, eating disorders, 196
eating disorders, 193, 196, 200, 205	vasopressin, personality disorders, 306	ziprasidone
major depressive disorder (MDD), 54, 56, 61–63	venlafaxine	bipolar disorder, 44, 48
panic disorder, 74, 76–78	eating disorders, 202	obsessive–compulsive disorder (OCD), 154
personality disorders, 284, 286–288	generalized anxiety disorder (GAD), 111–112, 115–117, 119	personality disorders, 295, 302
post-traumatic stress disorder (PTSD), 174, 176–177	major depressive disorder (MDD), 54, 56, 59	schizophrenia, 20–22, 25, 29
social anxiety disorder (SAD), 96	nicotine dependence, 219	zonisamide
trifluoperazine, personality disorders, 287	obsessive–compulsive disorder (OCD), 143, 147	eating disorders, 202–203
triiodothyronine (T3), major depressive disorder (MDD), 62	panic disorder, 74–76, 78–81	generalized anxiety disorder (GAD), 119
	personality disorders, 300–301, 305	zotepine, schizophrenia, 20
	post-traumatic stress disorder (PTSD), 174, 176, 179, 182, 184–185	